We’re proud to share that Velocity was named a top enrolling site network for Q1 2025 by AstraZeneca, with the highest number of randomizations across their biopharma portfolio.
This recognition is a testament to the dedication of our teams around the world who work every day to ensure clinical trial participants are supported, engaged, and enrolled with care and efficiency.
We’re honored to partner with AstraZeneca in advancing innovative therapies — and even more proud to play a leading role in getting those therapies to the patients who need them most.
